Related Experiment Video

Updated: Jun 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Molecular blocking of CD23 supports its role in the pathogenesis of arthritis

Jérôme Rambert1, Maria Mamani-Matsuda, Daniel Moynet

  • 1Groupe Thérapeutiques d'inflammation et d'infection, Laboratoire d'Immunologie et de Parasitologie, UFR Sciences Pharmaceutiques, Université Bordeaux 2, Bordeaux, France.

Plos One
|March 13, 2009
PubMed

Insights

A novel CD23-blocking peptide (p30A) effectively inhibits inflammatory responses in macrophages. This peptide shows promise for treating conditions like arthritis and allergic reactions by targeting CD23 activation.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • CD23, also known as Fc epsilonRII, is a receptor involved in immune responses, including IgE regulation and cell differentiation.
  • It is expressed on various cells and implicated in allergic reactions and rheumatoid arthritis.
  • The precise role of CD23 in disease pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the therapeutic potential of CD23-blocking peptides.
  • To evaluate the efficacy of a specific CD23-blocking peptide (p30A) in preclinical models of inflammation.

Main Methods:

  • Generation of heptapeptidic countrestructures of human CD23.
  • In vitro studies using human and rat macrophages to assess peptide effects on cytokine transcription and IgE-mediated activation.
  • In vivo studies in a rat model of arthritis to evaluate the peptide's clinical efficacy and bone protection.

Main Results:

  • CD23-specific peptides significantly reduced inflammatory cytokine transcription and mediator release in macrophages.
  • The peptide inhibited IgE-mediated activation of CD23(+) macrophages.
  • In vivo, the CD23-blocking peptide ameliorated arthritis clinical scores and prevented bone destruction in a dose-dependent manner.

Conclusions:

  • CD23-blocking peptide (p30A) effectively inhibits monocyte/macrophage activation without toxicity.
  • Targeting CD23 with antagonistic peptides can decrease inflammatory markers.
  • This approach holds potential clinical value for treating CD23-associated human arthritis and allergic diseases.
Abstract

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...